Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Deimos Biosciences
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Deimos Biosciences exclusively holds global rights (excluding Asia-Pacific) to develop, manufacture, and commercialize lerociclib—a CDK4/6 inhibitor—for radioprotective uses; animal studies suggest improved survival after radiation exposure. Clinical results have not been publicly disclosed, indicating preclinical status[3][4][5][7].
- Therapeutic areas
- Other
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
G1 Therapeutics
Beyond the preview
Go deeper on Deimos Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deimos Biosciences.